3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
4
Terminated
1
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stress Disorders, Post-Traumatic
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colorectal Neoplasms
1
Interventions
Irinotecan
58
Bevacizumab
56
Oxaliplatin
49
Leucovorin
49
Fluorouracil
49
Capecitabine
45
Cetuximab
44
pembrolizumab
23
IFL protocol
15
Nivolumab
11
regorafenib
10
Panitumumab
10
Celecoxib
8
Radiotherapy
7
Cyclophosphamide
7
atezolizumab
6
Surgical Procedures, Operative
6
Gemcitabine
6
Folfox protocol
6
Colonoscopy
6
trifluridine tipiracil drug combination
5
Neoadjuvant Therapy
5
Metformin
5
Immunohistochemistry
5
Biopsy
5
tislelizumab
4
spartalizumab
4
durvalumab
4
Trastuzumab
4
Mitomycin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colorectal Neoplasms
×
Palliative Care
×
Clear all
NCT03652298
2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2
Terminated
19 enrolled